lurasidone vs quetiapine
Latuda and Seroquel, compared on what the public record actually supports: who takes each one, who pays, what the labels warn, and what the litigation record holds. Sources on every number.
What this page will not do is rank them. For most same-class pairs, head-to-head efficacy differences are smaller than the rankings look — the largest network meta-analysis ever run (21 antidepressants, 522 trials) found every drug beat placebo and the gaps between drugs mostly modest and uncertain. Which one fits you turns on your history, your other medications, and side-effect trade-offs — a prescriber conversation. This page arms that conversation; here are the questions worth taking into it →
lurasidone (Latuda)
atypical antipsychotic
- FDA approval
- 2010 · full approval journey →
- Who takes it (US, 2021)
- 385,353 patients · 2,433,438 prescriptions (ClinCalc/MEPS)2014 → 2021: up 66% (1,466,825 → 2,433,438 prescriptions)
- Who pays (2024)
- Medicare: 853,499 claims · 124,110 beneficiariesMedicaid: ≥1,109,001 prescriptionsCommercial claims: not published in any public dataset — a real absence, not a zero.
- Boxed warning
- Yes — on the current FDA label. read it in context →
- Adverse-event reports (FAERS)
- Caveat first: FAERS counts unverified REPORTS, not patients or rates — no denominator, and attention inflates reporting. Never compare these counts head-to-head; a longer-marketed, more-prescribed drug accumulates more reports by exposure alone. how to read FAERS →20,803 all-time reports; most-reported terms: off label use, drug ineffective, anxiety
- Legal & safety record
- no dedicated record page yet; the journey page carries label history
quetiapine (Seroquel)
atypical antipsychotic
- FDA approval
- 1997 · full approval journey →
- Who takes it (US, 2024)
- 1,849,066 patients · 8,669,046 prescriptions (ClinCalc/MEPS)2014 → 2024: down 24% (11,456,968 → 8,669,046 prescriptions)
- Who pays (2024)
- Medicare: 9,859,922 claims · 1,488,315 beneficiariesMedicaid: ≥6,033,466 prescriptionsCommercial claims: not published in any public dataset — a real absence, not a zero.
- Boxed warning
- Yes — on the current FDA label. read it in context →
- Adverse-event reports (FAERS)
- Caveat first: FAERS counts unverified REPORTS, not patients or rates — no denominator, and attention inflates reporting. Never compare these counts head-to-head; a longer-marketed, more-prescribed drug accumulates more reports by exposure alone. how to read FAERS →191,484 all-time reports; most-reported terms: drug ineffective, off label use, toxicity to various agents
- Legal & safety record
- the full litigation & recall record →
Where these numbers come from
- Patients and prescriptions: ClinCalc DrugStats (federal MEPS survey), latest published year — counts of people filling prescriptions, not outcomes.
- Medicare/Medicaid: CMS public datasets; commercial insurance publishes no per-drug series, so it renders as an absence, never a synthesized number.
- Label facts: the drugs' current FDA labels via DailyMed — quoted in context on each drug's approval-journey page.
- FAERS: openFDA — reports, never rates; the caveat travels above every count.
- Litigation: court records and regulator documents only, on the linked record pages; settled is never adjudicated.
Explore both drugs in depth: /m/lurasidone · /m/quetiapine · or the whole library →